GW expects full-year profit on earlier German launch plans for Sativex
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals says it now expects to record a full-year profit as opposed to a small loss as launch plans in Germany for its cannabis-based multiple sclerosis-related spasticity treatment Sativex "are progressing faster than anticipated" by its marketing partner Almirall.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.